Thrombosis Research
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
A Point-of-Care Assay for Measuring Thrombin Activity in Finger-Prick Whole Blood
2019
-
Deep Mutational Scan of VWF to Define Mutations that Enhance or Impair Secretion
2019
-
Investigating the resistance of ADAMTS13 towards Alpha 2-Macroglobulin
2019
-
Mapping the Interactome of the Metalloprotease ADAMTS13 in Plasma using In-Vitro BioID
2019
-
Prevalence of Pulmonary Embolism in Patients Accessing the Emergency Department, Reported by Country of Study: A Systematic Review and Meta-Analysis
2019
-
Risks and Benefits of Antithrombotic Therapy in Polycythemia Vera: A Systematic Review
2019
-
Thrombus Stability Explains the Factor V Leiden Paradox: A Mouse Model
2019
-
12. Abstract Title: Factor V Leiden Mutation Stabilizes Thrombi and Reduces Embolization in Mice
2018
-
13. Abstract Title: Identifying patient values and expectations for pulmonary embolism CT scanning in the emergency department
2018
-
2. Abstract Title: Canadian Practice Patterns on Use of Catheter-Directed Thrombolysis for Lower Limb Deep Vein Thrombosis: Results of a National Survey
2018
-
9. Abstract Title: Measurement of anti-factor Xa direct oral anticoagulant levels in the plasma samples from the perioperative anticoagulant use for surgery evaluation (PAUSE) study
2018
-
Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the ‘select-d’ Pilot Trial
2018
-
Cell surface GRP78 activation by anti-GRP78 autoantibodies confers prostate tumour growth via tissue factor activation
2018
-
Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial
2018
-
Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial
2018
-
Planning the APPLE (AntiPhosPholipid syndrome Low-molecular-weight heparin pregnancy loss Evaluation) clinical trial: an international survey of physicians
2017
-
Incidence and risk factors for venous thromboembolism in patients with acute spinal cord injury: A retrospective study
2016
-
Influence of cancer on the efficacy and safety of dabigatran vs. warfarin for the acute and extended treatment of venous thromboembolism
2014
-
New anticoagulants in atrial fibrillation management
2013
-
C0129 Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: A systematic review and meta-analysis of the literature
2012
-
C0306 Accuracy of emergency physician’ performed ultrasonography in the diagnosis of deep vein thrombosis: A systematic review and a meta-analysis of the literature
2012
-
C0307 Baseline characteristics and management of patients with splanchnic vein thrombosis: Results of an international registry
2012
-
C0322 Factors associated with therapeutic strategies in patients with splanchnic vein thrombosis: Results of an international registry
2012
-
Binding of anti-GRP78 autoantibodies to cell surface GRP78 promotes cancer progression by activating tissue factor procoagulant activity
2012
-
The pathogenesis of warfarin-associated venous limb ischemia and gangrene complicating cancer: clinical and laboratory parallels with heparin-induced thrombocytopenia (HIT)
2012
-
OC-03 Randomized phase II trial of an oral factor Xa inhibitor in patients with metastatic cancer on chemotherapy
2010
-
North American and British guidelines for anti-thrombotic therapy: are we reaching consensus?
2009
-
O8 Predicting DVT in pregnancy: out in “left” field?
2009
-
PO-40 PRODIGE: a randomized placebo-controlled trial of long-term thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma: updated results
2007
-
PO-44 Incidence of venous thromboembolism in patients undergoing thoracotomy for cancer
2007
-
Anticoagulant therapy for the thrombotic complications of the antiphospholipid antibody syndrome
2004
-
Mechanisms of neuronal damage in SLE and APLS: Therapeutic implications
2004
-
Optimal therapy of patients with antiphospholipid antibodies and thrombosis: The next steps
2004
-
Phospholipid antibodies and cognitive function: Patterns and prediction
2004
-
Current anticoagulant therapy—unmet clinical needs
2003
-
Pharmacokinetic Profile of a Low-Molecular Weight Heparin (Reviparin) in Pregnant Patients
2000
-
Accuracy and clinical utility of anticoagulation induction using a computer generated system compared with manual dosing in hospitalized patients
1998
-
Fasting plasma homocysteine levels do not predict the occurrence of deep vein thrombosis after elective hip replacement surgery
1998
-
The role of coagulation factors II, V, VII, and X in the response to oral anticoagulants in patients following heart valve replacement
1998
-
EFFECTS OF HEPARIN AND DERMATAN SULFATE ON INJURED VESSEL WALL HYPERPLASIA
1993
-
MECHANISMS FOR THE ANTITHROMBOTIC EFFECTS OF GLYCOSAMINOGLYCANS
1993
-
RELATIVE EFFECTS OF HEPARIN AND SULODEXIDE ON PREVENTION OF THROMBUS FORMATION AND GROWTH
1993
-
SUSTAINED ANTITHROMBOTIC ACTIVITY OF HIRUDIN AFTER ITS PLASMA-CLEARANCE - COMPARISON WITH HEPARIN
1993
-
Comparative effects of heparin and LMW heparin on hemostasis
1991
-
CLINICAL-TRIALS WITH LOW-MOLECULAR-WEIGHT HEPARIN IN VENOUS THROMBOSIS
1986
-
POSITIVE EFFECT ON HEMOSTASIS BY 1-DEAMINO-8-D-ARGININE VASOPRESSIN (DDAVP) IN CONGENITAL PLATELET-FUNCTION DEFECTS
1986
-
THERAPEUTIC RANGE FOR CONTROL OF ORAL ANTICOAGULANT-THERAPY
1986
-
Association between the simplified Pulmonary Embolism Severity Index (sPESI) score and hospitalization in emergency department patients diagnosed with pulmonary embolism..
245:109234.
2024
-
Knowledge and raising awareness are the CURES for alleviating sex disparities in PE care..
243:109147.
2024
-
Validation of a Simplified Diagnostic Algorithm for Deep Vein Thrombosis.
242:109165.
2024
-
Low recurrent thrombosis rates in single positive antiphospholipid syndrome regardless of type of anticoagulation.
237:88-93.
2024
-
Considerations for instituting pediatric pulmonary embolism response teams: A tool kit.
236:97-107.
2024
-
Pharmacokinetics of direct oral anticoagulants after bariatric surgery: A retrospective cohort study.
235:15-17.
2024
-
Comparing U.S. and Canadian treatment patterns on venous thromboembolism outcomes in the GARFIELD-VTE registry.
232:123-132.
2023
-
Serial D-dimers after anticoagulant cessation in unprovoked venous thromboembolism: Data from the REVERSE cohort study.
231:32-38.
2023
-
Direct oral anticoagulants for the treatment of splanchnic vein thrombosis – A systematic review and meta-analysis.
229:209-218.
2023
-
Laboratory and demographic predictors of functional assay positive status in suspected heparin-induced thrombocytopenia: A multicenter retrospective cohort study.
229:198-208.
2023
-
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE.
222:31-39.
2023
-
Corrigendum to “Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE” [Thromb. Res. 2020 Jul; 191:103–112].
216:129-129.
2022
-
Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels.
215:1-4.
2022
-
Risk of intracranial hemorrhage between different direct oral anticoagulants in older patients seen in the emergency department with a head injury: A population-based cohort study.
214:47-52.
2022
-
Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study.
214:122-131.
2022
-
Efficacy of parenteral formulations of desmopressin in the treatment of bleeding disorders: A systematic review.
213:16-26.
2022
-
The association between anticoagulation and adverse outcomes after a positive SARS-CoV-2 test among older outpatients: A population-based cohort study.
211:114-122.
2022
-
Corrigendum to “Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE” [Thromb. Res. 2021 May;201:63–72].
209:105-105.
2022
-
Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis.
208:58-65.
2021
-
Special series on challenging anticoagulation cases: Experience counts when guidelines fall short.
208:198-198.
2021
-
Challenging anticoagulation cases: A case of heparin-induced-thrombocytopenia in the first trimester of pregnancy.
207:58-61.
2021
-
Heparin induced thrombocytopenia in relation to SARS-CoV-2 infection and ABO blood group.
207:62-65.
2021
-
VIPIT versus VITT: what's in a name?.
207:158-160.
2021
-
Derivation and validation of predictors of oral anticoagulant-related adverse events in seniors transitioning from hospital to home.
206:18-28.
2021
-
Double high-dose immunoglobulin for ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia.
206:14-17.
2021
-
Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia.
204:40-51.
2021
-
The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE.
203:155-162.
2021
-
Initiation of anticoagulation in atrial fibrillation by primary care physicians: Results of a telephone survey.
202:176-181.
2021
-
Are the correct outcomes being measured in studies of oral anticoagulants? A systematic survey.
201:30-49.
2021
-
COVID-19 in thrombosis research: An editorial perspective.
201:147-150.
2021
-
Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE.
201:63-72.
2021
-
PO-36 Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomisation of the SELECT-D trial.
200:S36-S36.
2021
-
Challenging anticoagulation cases: A case of acute pulmonary embolism in a patient with chronic thrombocytopenia.
198:83-85.
2021
-
Weight-adjusted tinzaparin for venous thromboembolism prophylaxis in bariatric surgery patients weighing 160 kg or more.
198:1-6.
2021
-
A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
196:550-558.
2020
-
COVID-19 versus HIT hypercoagulability.
196:38-51.
2020
-
Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review.
194:240-245.
2020
-
The challenges and lessons learned in conducting clinical trials in pregnant women with antiphospholipid syndrome.
194:54-56.
2020
-
The role of fluid-phase immune complexes in the pathogenesis of heparin-induced thrombocytopenia.
194:135-141.
2020
-
Adverse outcomes associated with managing suspected heparin induced thrombocytopenia in the critically ill.
193:218-220.
2020
-
Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE.
191:103-112.
2020
-
Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19].
191:156-159.
2020
-
Does cell-free DNA promote coagulation and inhibit fibrinolysis in patients with unprovoked venous thromboembolism?.
186:13-19.
2020
-
Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study.
185:13-19.
2020
-
Subsegmental pulmonary embolism: May not be a killer but indicates significant risk.
185:180-182.
2020
-
A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients.
184:31-37.
2019
-
Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis.
184:58-61.
2019
-
Frequency of arterial thromboembolism in populations with malignancies: A systematic review.
184:16-23.
2019
-
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition.
184:44-49.
2019
-
Results of a multinational survey of diagnostic and management practices of thromboembolic pulmonary embolism in children.
183:98-105.
2019
-
Addressing emotional and physical distress after pulmonary embolism.
182:184-184.
2019
-
Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding.
182:12-19.
2019
-
P6. Abstract Title: Risks and Benefits of Antithrombotic Therapy in Polycythemia Vera: A Systematic Review.
182:6-6.
2019
-
Structure and function of a perioperative anticoagulation management clinic.
182:167-174.
2019
-
XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
176:125-132.
2019
-
Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: A systematic review and meta-analysis.
175:102-109.
2019
-
Accuracy of age-adjusted D-dimer to rule out deep vein thrombosis in the elderly.
174:148-150.
2019
-
Prevalence and correlates of bleeding and emotional harms in a national US sample of patients with venous thromboembolism: A cross-sectional structural equation model.
172:181-187.
2018
-
Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time.
171:62-67.
2018
-
The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A.
170:53-59.
2018
-
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients.
170:75-83.
2018
-
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin.
168:121-129.
2018
-
Antiplatelet use in patients with essential thrombocythemia: A survey of opinion and Canadian practice.
167:6-8.
2018
-
Management of cancer-associated upper extremity deep vein thrombosis with and without venous catheters at a tertiary care center.
166:92-95.
2018
-
An opinion on the benefits of concomitant oral contraceptive therapy in premenopausal women treated with oral anticoagulants.
165:14-17.
2018
-
Systematic review of efficacy and safety of retrievable inferior vena caval filters.
165:79-82.
2018
-
Management of recurrent venous thromboembolism in patients with cancer: A review.
164:S172-S177.
2018
-
Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
163:132-137.
2018
-
Management of direct oral anticoagulant associated bleeding: Results of a multinational survey.
163:19-21.
2018
-
Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study.
163:41-46.
2018
-
A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2).
162:88-92.
2018
-
Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.
162:7-14.
2018
-
Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study.
162:104-109.
2018
-
Optimal timing of starting thromboprophylaxis for patients with acute spinal cord injury: A survey of Canadian spine surgeons.
160:38-40.
2017
-
Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis.
160:97-104.
2017
-
The importance of post thrombotic syndrome as an outcome after deep venous thrombosis: A survey of Canadian thrombosis clinicians.
159:13-15.
2017
-
Assessing renal function in patients receiving DOACs: Cockcroft-Gault versus estimated glomerular filtration rate.
157:165-166.
2017
-
Management of hereditary antithrombin deficiency in pregnancy.
157:41-45.
2017
-
Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study.
155:23-27.
2017
-
Indications, complications and outcomes of inferior vena cava filters: A retrospective study.
153:123-128.
2017
-
Performance characteristics of an automated latex immunoturbidimetric assay [HemosIL ® HIT-Ab (PF4-H) ] for the diagnosis of immune heparin-induced thrombocytopenia.
153:108-117.
2017
-
Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study.
152:44-48.
2017
-
The impact of the endothelial protein C receptor on thrombin generation and clot lysis.
152:30-37.
2017
-
Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism.
151:67-71.
2017
-
Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.
149:29-37.
2017
-
Impact of thrombophilia screening on venous thromboembolism management practices.
149:76-80.
2017
-
Retinal vein thrombosis: The Internist's role in the etiologic and therapeutic management.
148:118-124.
2016
-
Incidence and risk factors for venous thromboembolism in patients with acute spinal cord injury: A retrospective study.
147:97-101.
2016
-
Acute intraoperative HIT during heart surgery: Why so rare?.
146:110-112.
2016
-
Ciraparantag for enoxaparin reversal: Adding to the evidence.
146:106-107.
2016
-
D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment.
146:119-125.
2016
-
Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation.
145:143-148.
2016
-
An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150 mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery.
144:158-164.
2016
-
Safe bridging to warfarin in heparin-induced thrombocytopenia.
144:226-228.
2016
-
Use of decision aids for shared decision making in venous thromboembolism: A systematic review.
143:71-75.
2016
-
Low molecular weight heparin to prevent postpartum venous thromboembolism: A pilot study to assess the feasibility of a randomized, open-label trial.
142:17-20.
2016
-
Factor XI and factor XII as targets for new anticoagulants.
141:S40-S45.
2016
-
Panax notoginseng saponin is superior to aspirin in inhibiting platelet adhesion to injured endothelial cells through COX pathway in vitro.
141:146-152.
2016
-
Demand on-demand testing for the diagnosis of heparin-induced thrombocytopenia.
140:163-164.
2016
-
Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events.
140:81-88.
2016
-
Management of bleeding complications in patients with cancer on DOACs.
140:S142-S147.
2016
-
Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial.
139:77-81.
2016
-
Enhanced TRAP-induced platelet aggregation with dabigatran — Clinical perspective.
138:61-62.
2016
-
Women’s values and preferences and health state valuations for thromboprophylaxis during pregnancy: A cross-sectional interview study.
140:22-29.
2016
-
An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes.
136:1053-1054.
2015
-
Risk of Stent Thrombosis and Major Bleeding with Bivalirudin Compared with Active Control: A Systematic Review and Meta-analysis of Randomized Trials.
136:1087-1098.
2015
-
Systematic review of anticoagulant treatment of catheter-related thrombosis.
136:1103-1109.
2015
-
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage.
136:1040-1044.
2015
-
Adherence to mechanical thromboprophylaxis after surgery: A systematic review and meta-analysis.
136:723-726.
2015
-
Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS).
136:S13-S18.
2015
-
Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: Meta-analysis of randomized controlled trials: Comment.
136:180-181.
2015
-
Declining Long-term Risk of Adverse Events after First-time Community-presenting Venous Thromboembolism: The Population-based Worcester VTE Study (1999 to 2009).
135:1100-1106.
2015
-
Anticoagulation for stroke prevention in new atrial fibrillation after coronary artery bypass graft surgery.
135:841-845.
2015
-
Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
135:243-248.
2015
-
Thrombin generation test in children and adolescents with chronic liver disease.
135:382-387.
2015
-
Rivaroxaban for treatment of HIT: A riveting first experience.
135:1-2.
2015
-
Women’s values and preferences for thromboprophylaxis during pregnancy: a comparison of direct-choice and decision analysis using patient specific utilities.
136:341-347.
2015
-
Alpha-1 proteinase inhibitor M358R reduces thrombin generation when displayed on the surface of cells expressing tissue factor.
134:1142-1149.
2014
-
Rofecoxib does not appear to increase the risk of venous thromboembolism: A systematic review of the literature.
134:997-1003.
2014
-
Thrombosis: A major contributor to global disease burden.
134:931-938.
2014
-
Reduced-dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: A randomized trial.
134:814-818.
2014
-
Distal deep vein thrombosis – a benign disease?.
134:5-6.
2014
-
Voting with your fondaparinux.
134:3-4.
2014
-
An Instrument-based Immunoassay with an Appropriate Normal Range: Minimizing HIT Overdiagnosis.
133:961-962.
2014
-
Platelet Microparticle Generation Assay for Detection of HIT Antibodies: Advance, Retreat, or Too Soon to Tell?.
133:957-958.
2014
-
Appropriate Assessment of the Functional Consequences of Platelet Cyclooxygenase-1 Inhibition by Aspirin in vivo.
133:697-698.
2014
-
Potential antidotes for reversal of old and new oral anticoagulants.
133:S158-S166.
2014
-
Reversal of New, Factor-specific Oral Anticoagulants by rFVIIa, Prothrombin Complex Concentrate and Activated Prothrombin Complex Concentrate: A Review of Animal and Human Studies.
133:705-713.
2014
-
Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: A systematic review and meta-analysis.
133:682-687.
2014
-
Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes.
132:770-775.
2013
-
Erratum to “Small intestinal bacterial overgrowth and warfarin dose requirement variability” [Thromb. Res. 126 (1) (2010) 12–17].
132:e167-e167.
2013
-
Nonadherence with INR Monitoring and Anticoagulant Complications.
132:e124-e130.
2013
-
Effective, selective and specific inhibition of COX-1 may overcome the “aspirin paradox”.
132:1-2.
2013
-
Anticoagulation management in patients with mechanical heart valves having pacemaker or defibrillator insertion.
131:300-303.
2013
-
Adjudication of bleeding outcomes in an international thromboprophylaxis trial in critical illness.
131:204-209.
2013
-
Dalteparin Low Molecular Weight Heparin (LMWH) in ovarian cancer: A phase II randomized study.
130:894-900.
2012
-
Accuracy and safety of 99mTc-labeled anti-D-dimer (DI-80B3) Fab’ fragments (ThromboView®) in the diagnosis of deep vein thrombosis: A phase II study.
130:381-389.
2012
-
Aspirin response variability after major orthopedic surgery.
130:216-220.
2012
-
Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement.
130:166-172.
2012
-
Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study.
129:715-719.
2012
-
Determination of alpha-2-macroglobulin complexes by a new immuno-activity assay.
129:635-640.
2012
-
Hemodialysis-Associated Acute Systemic Reactions and Heparin-Induced Thrombocytopenia.
129:405-406.
2012
-
Prothrombin complex concentrate (PCC, Octaplex®) in patients requiring immediate reversal of vitamin K antagonist anticoagulation.
129:526-529.
2012
-
Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy.
129:146-151.
2012
-
Statins in the prevention of venous thromboembolism: A meta-analysis of observational studies.
128:422-430.
2011
-
Carotid artery dissections: Thrombosis of the false lumen.
128:317-324.
2011
-
Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay.
128:256-260.
2011
-
Combination warfarin-ASA therapy: Which patients should receive it, which patients should not, and why?.
127:513-517.
2011
-
Management of deep vein thrombosis diagnosed during active labour.
127:170-170.
2011
-
Factor Xa and thrombin as targets for new oral anticoagulants.
127:S5-S12.
2011
-
Neonatal Systemic Venous Thrombosis.
126:471-476.
2010
-
Antithrombotic Activity of the Novel Oral Anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in Animal Models.
126:e383-e388.
2010
-
Monkey business for hemophilia management.
126:365-366.
2010
-
Serum Lipoprotein (a) Levels in Patients with First Unprovoked Venous Thromboembolism is not Associated with Subsequent Risk of Recurrent VTE.
126:222-226.
2010
-
Use of the Delphi method to establish guidelines for treatment of thrombosis.
126:79-80.
2010
-
Small intestinal bacterial overgrowth and warfarin dose requirement variability.
126:12-17.
2010
-
Mice with deleted multimerin 1 and α-synuclein genes have impaired platelet adhesion and impaired thrombus formation that is corrected by multimerin 1.
125:e177-e183.
2010
-
Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range.
125:393-397.
2010
-
Periprocedural anticoagulation practices in warfarin-treated patients who require elective angiography with or without percutaneous coronary intervention: A retrospective chart review.
125:351-352.
2010
-
Potential of new anticoagulants in patients with cancer.
125:S30-S35.
2010
-
Role of the tissue factor pathway in the biology of tumor initiating cells.
125:S44-S50.
2010
-
Thromboprophylaxis during chemotherapy: NO.
125:S16-S16.
2010
-
Tissue factor microparticles and haemophilia.
125:S67-S69.
2010
-
Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients.
125:e128-e131.
2010
-
Decreasing warfarin sensitivity during the first three months after heart valve surgery: Implications for dosing.
125:224-229.
2010
-
Anti-prothrombin antibodies and other acquired antibodies associated with thrombosis in children.
125:2-3.
2010
-
Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET).
124:e1-e5.
2009
-
Hypercoagulability after trauma: Hemostatic changes and relationship to venous thromboembolism.
124:281-287.
2009
-
Safety of continuing warfarin therapy during cataract surgery: A systematic review and meta-analysis.
124:292-299.
2009
-
Definition of major bleeding used by US anticoagulation clinics.
124:239-240.
2009
-
Cervical artery dissection: Pathology, epidemiology and management.
123:810-821.
2009
-
Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: A systematic review of randomized trials.
123:687-696.
2009
-
Unanswered questions in venous thromboembolism.
123:S2-S10.
2009
-
Location of the multimerin 1 binding site in coagulation factor V: An update.
123:352-354.
2008
-
Preventing and managing bleeding complications in anticoagulated patients: A case based approach.
123:S42-S45.
2008
-
The top 4 advances in antithrombotic care in the last year.
123:S2-S6.
2008
-
Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients.
123:177-183.
2008
-
Enoxaparin for neonatal thrombosis: A call for a higher dose for neonates.
122:826-830.
2008
-
Has the incidence of deep vein thrombosis in patients undergoing total hip/knee arthroplasty changed over time? A systematic review of randomized controlled trials.
123:24-34.
2008
-
Heparin and low molecular weight heparins as scaffolds for assembling antithrombin and serine proteases.
123:5-7.
2008
-
Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
122:211-220.
2008
-
Reading between the (Guidelines). Management of submassive pulmonary embolism in the first trimester of pregnancy.
121:705-707.
2008
-
Reversal of vitamin K antagonist-associated coagulopathy: A survey of current practice.
122:864-866.
2008
-
The anti-inflammatory effects of heparin and related compounds.
122:743-752.
2008
-
Thromboembolism in children with lymphoma.
122:459-465.
2008
-
Treatment of endothelium with the chemotherapy agent vincristine affects activated protein C generation to a greater degree in newborn plasma than in adult plasma.
122:418-426.
2008
-
Use of a single anti-Xa calibration curve is adequate for monitoring enoxaparin and tinzaparin levels in children.
122:867-869.
2008
-
Utility of aPTT in monitoring unfractionated heparin in children.
122:135-136.
2008
-
Aspirin resistance.
120:337-346.
2007
-
Combined administration of barbourin–albumin and hirudin–albumin fusion proteins limits fibrin(ogen) deposition on the rabbit balloon-injured aorta.
119:195-207.
2007
-
Covalent antithrombin–heparin complexes.
120:151-160.
2007
-
Effect of substrate and fibrin polymerization inhibitor on determination of plasma thrombin generation in vitro.
119:667-677.
2007
-
Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate.
119:715-721.
2007
-
Monitoring Unfractionated Heparin (UFH) therapy: Which Anti Factor Xa assay is appropriate?.
120:347-351.
2007
-
Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada.
119:145-155.
2007
-
Optimal reversal of vitamin K antagonists.
119:15-16.
2007
-
Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: The appropriate use and barriers to oral anticoagulant therapy.
120:663-669.
2007
-
Reversal of anti-thrombin activity using protamine sulfate. Experience in a neonate with a 10-fold overdose of enoxaparin.
120:303-305.
2007
-
The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression.
120:S82-S91.
2007
-
The use of low molecular weight heparins in pediatrics: Two cases that highlight potential risks to patient safety.
121:281-282.
2007
-
Age-related differences in heparin response.
118:741-745.
2006
-
Bleeding in patients with renal insufficiency: A practical guide to clinical management.
118:423-428.
2006
-
Interobserver agreement on ultrasound measurements of residual vein diameter, thrombus echogenicity and Doppler venous flow in patients with previous venous thrombosis.
117:241-247.
2006
-
Investigating serpin–enzyme complex formation and stability via single and multiple residue reactive centre loop substitutions in heparin cofactor II.
117:447-461.
2006
-
Low-molecular-weight heparins for the treatment of acute coronary syndrome and venous thromboembolism in patients with chronic renal insufficiency.
118:409-416.
2006
-
Managing thromboembolism and bleeding in patients with impaired renal function: A common but under-recognized clinical problem.
118:381-383.
2006
-
Pediatric edition thrombosis research.
118:1-2.
2006
-
Recognition, treatment, and prevention of heparin-induced thrombocytopenia: Review and update.
118:165-176.
2006
-
Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.
117:507-515.
2006
-
Thromboembolic complications in children with cancer.
118:137-152.
2006
-
Thromboembolic complications in the nephrotic syndrome: Pathophysiology and clinical management.
118:397-407.
2006
-
Thromboembolism and anticoagulant management in hemodialysis patients: A practical guide to clinical management.
118:385-395.
2006
-
Uremic bleeding: Pathophysiology and clinical risk factors.
118:417-422.
2006
-
Activated protein C resistance and low molecular weight lipoprotein (a): dual pathogens for atherothrombosis?.
115:491-494.
2005
-
Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia.
116:121-126.
2005
-
Evidence based treatment of the antiphospholipid syndromeII. Optimal anticoagulant therapy for thrombosis.
115:3-8.
2005
-
Heparin compromises streptokinase-induced arterial patency in rabbits.
115:427-434.
2005
-
Recombinant FVIIa in children with liver disease.
116:185-197.
2005
-
Role of thrombophilic risk factors in children with non-stroke cerebral palsy.
116:133-137.
2005
-
Evidence-based treatment of the antiphospholipid syndrome.
114:75-81.
2004
-
Heparin cofactor II is more sensitive than antithrombin to secretory impairment arising from mutations introduced into its carboxy-terminal region.
113:163-173.
2004
-
Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10.
113:205-209.
2004
-
Patient preferences for capillary vs. venous INR determination in an anticoagulation clinic: a randomized controlled trial.
114:161-165.
2004
-
Trimming of peripherally inserted central venous catheters may increase the risk of thrombosis.
113:175-177.
2004
-
A novel approach to thrombin inhibition.
109:S17-S22.
2003
-
Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.
110:73-82.
2003
-
Oral anticoagulants in patients with coronary artery disease: an inexpensive and effective strategy.
109:159-161.
2003
-
A cross-sectional study evaluating post-thrombotic syndrome in children.
111:227-233.
2003
-
A systematic review of economic analyses of low-molecular-weight heparin for the treatment of venous thromboembolism.
112:193-201.
2003
-
An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial.
109:85-92.
2003
-
An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial.
109:101-108.
2003
-
Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin–sodium) in pediatric patients.
109:93-99.
2003
-
Thrombosis in children with acute lymphoblastic leukemia.
111:125-131.
2003
-
Thrombosis in children with acute lymphoblastic leukemia.
111:199-212.
2003
-
Thrombosis in children with acute lymphoblastic leukemia.
111:321-327.
2003
-
Venous thromboembolism prophylaxis in medical inpatients: a retrospective chart review.
111:215-219.
2003
-
Treatment and prophylaxis of venous thromboembolism during pregnancy.
108:97-106.
2002
-
Oral-anticoagulant-related intracerebral hemorrhage.
108:31-36.
2002
-
Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians.
108:3-13.
2002
-
In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation.
107:241-244.
2002
-
Low-dose warfarin in rehabilitating stroke survivors.
107:287-290.
2002
-
Direct thrombin inhibitors.
106:V275-V284.
2002
-
Modulation of Clearance of Recombinant Serum Albumin by Either Glycosylation or Truncation.
99:613-621.
2000
-
Mutation of Any Site of N-Linked Glycosylation Accelerates the In Vivo Clearance of Recombinant Rabbit Antithrombin.
99:407-415.
2000
-
The Effects of Hormone Replacement Therapy on Thrombin Generation, Fibrinolysis Inhibition, and Resistance to Activated Protein C.
99:25-34.
2000
-
Optimal Dosing of Subcutaneous Unfractionated Heparin for the Treatment of Deep Vein Thrombosis.
97:395-403.
2000
-
The Binding of Unfractionated Heparin and Low Molecular Weight Heparin to Thrombin-Activated Human Endothelial Cells.
96:373-381.
1999
-
Effects of Cathepsin G Pretreatment of Platelets on their Subsequent Responses to Aggregating Agents.
95:315-323.
1999
-
Role of Secreted Adenosine Diphosphate in the Synergistic Effects of Cathepsin G on Human Platelets.
95:341-346.
1999
-
Accuracy of a Portable International Normalization Ratio Monitor in Outpatients Receiving Long-Term Oral Anticoagulant Therapy.
92:11-17.
1998
-
A Randomized Comparison of a Computer-Based Dosing Program with a Manual System to Monitor Oral Anticoagulant Therapy.
91:237-240.
1998
-
Evaluation of the Combination of a Bedside D-Dimer Assay and Enzyme-Linked Immunosorbent Soluble Fibrin Assay in Patients with Suspected Venous Thromboembolism.
88:291-297.
1997
-
IMPACT OF MUTATIONS AT THE P4 AND P5 POSITIONS ON THE REACTION OF ANTITHROMBIN WITH THROMBIN AND ELASTASE.
88:171-181.
1997
-
INHIBITION OF THROMBIN BY HIRUDIN GENETICALLY FUSED TO WILD-TYPE OR MUTANT ANTITHROMBIN.
84:419-429.
1996
-
Partial expression of GP Ib measured by flow cytometry in two patients with Bernard-Soulier syndrome.
76:441-450.
1994
-
Amino acid substitutions of the P2 residue of human antithrombin that either enhance or impair function.
75:293-305.
1994
-
Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: Importance of heparin cofactor II.
74:463-475.
1994
-
Characterization of a highly polymorphic trinucleotide short tandem repeat within the human antithrombin gene.
74:303-307.
1994
-
The direct binding of human factor VII in plasma to recombinant human tissue factor.
70:307-316.
1993
-
Complete nucleotide sequence of the cdna encoding rabbit coagulation factor VII.
69:231-238.
1993
-
Thrombolytic and haemorrhagic effects of bolus doses of rt-PA and A hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
70:s91.
1993
-
Heparin sensitivity and resistance in the neonate: An explanation.
63:85-98.
1991
-
The hypersensitivity to thrombin of platelets from diabetic rats is not due to increased thrombin binding.
61:469-475.
1991
-
Relationship between vessel wall 13-HODE synthesis and vessel wall thrombogenecity following injury: Influence of salicylate and dipyridamole treatment.
57:383-392.
1990
-
The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig.
56:529-539.
1989
-
Heparin clearance and ex vivo recovery in newborn piglets and adult pigs.
52:517-527.
1988
-
Evidence for a saturable mechanism of disappearance of standard heparin in rabbits.
46:835-844.
1987
-
The disappearance of a low molecular weight heparin fraction (cy 216) differs from standard heparin in rabbits.
46:845-853.
1987
-
Ddavp-induced correction of prolonged bleeding time in patients with congenital platelet function defects.
45:165-174.
1987
-
Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect.
43:491-495.
1986
-
The presence of plasma proteins facilitates the uptake of 125I-thrombin by the rabbit thoracic aorta endothelium.
43:73-86.
1986
-
Management of anti-thrombin III deficiency during pregnancy without administration of anti-thrombin III.
41:567-573.
1986
-
The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: Influence of dosage regimens in rabrits.
40:769-777.
1985
-
Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth.
40:81-89.
1985
-
Thrombolysis and fibrinolytic parameters during heparin treatment of deep vein thrombosis.
39:607-612.
1985
-
Approaches to the measurement of the response to Factor VIII concentrate infusion.
39:429-437.
1985
-
An evaluation of suloctidil in the prevention of deep vein thrombosis in neurosurgical patients.
39:173-181.
1985
-
Thrombogenetic studies of bioprosthetic heart valve surfaces I. In vitro platelet adhesion in a static system.
38:163-172.
1985
-
Effect of ticlopidine on platelet aggregation, adherence to damaged vessels, thrombus formation and platelet survival.
37:29-43.
1985
-
The isolation of prothrombin, factor IX and factor X from human factor IX concentrates.
36:537-547.
1984
-
Outcome of abnormal impedance plethysmography results in patients with proximal-vein thrombosis: Frequency of return to normal.
36:259-263.
1984
-
A comparison of the anti thrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation.
35:613-625.
1984
-
Effect of suloctidil on platelet function in patients with shortened platelet. Survival time.
35:397-406.
1984
-
A study of the bioavailability and platelet inhibitory effects of a new enteric-coated acetylsalicylic acid preparation.
34:561-566.
1984
-
Local venous infusion of streptokinase in DVT.
34:213-216.
1984
-
Studies on the frequency of heparin-associated thrombocytopenia.
33:439-443.
1984
-
The effect of aspirin on the size of the hemostatic plug.
32:267-273.
1983
-
The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination.
31:51-67.
1983
-
Dipyridamole disposition after chronic administration: Effect of aspirin.
29:137-143.
1983
-
The sex-related differences in aspirin pharmacokinetics in rabbits and man and its relationship to antiplatelet effects.
29:125-139.
1983
-
Variability in the human drug response.
29:3-15.
1983
-
The effect of prostaglandins E1, I2 and F2α on the shape and phosphatidylinositol-4,5-bisphosphate metabolism of washed rabbit platelets.
28:731-740.
1982
-
Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction.
28:401-409.
1982
-
Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma.
28:487-497.
1982
-
Inhibition of arterial thrombosis and platelet function by nafazatrom.
28:157-170.
1982
-
Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin-iii affinity heparin fraction.
27:679-690.
1982
-
Thrombin activation rate constant: One-stage chromogenic assay for the extrinsic system.
26:1-12.
1982
-
Aspirin inhibits platelet function independent of the acetylation of ciclo-oxygenase.
25:363-373.
1982
-
ASPIRIN INHIBITS PLATELET-FUNCTION INDEPENDENT OF THE ACETYLATION OF CYCLO-OXYGENASE.
25:263-373.
1982
-
Sex-related differences in the efficacy of acetylsalicylic acid (ASA): The absorption of ASA and its effect on collagen-induced thromboxane B2 generation.
24:163-168.
1981
-
Activation of factor X and prothrombin in antithrombin-III depleted plasma: The effects of heparin.
23:331-345.
1981
-
Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin.
21:169-174.
1981
-
The factor VIII-independent activation of factor X by factors IXa and VII in plasma.
21:23-33.
1981
-
Inactivation of thrombin by antithrombin III on a heparinized biomaterial.
20:543-554.
1980
-
The use of the evacuated blood collection tube in the determination of plasma betathromboglobulin.
20:693-695.
1980
-
Differences in inhibition of PGI2 production by aspirin in rabbit artery and vein segments.
20:447-460.
1980
-
Ontogeny of mouse and rat antithrombin III.
20:417-424.
1980
-
The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III.
20:391-403.
1980
-
Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography.
20:77-83.
1980
-
A comparison of the quantitative ristocetin von willebrand factor assay by using fresh and fixed platelets.
18:477-483.
1980
-
Altered inactivation of trinitrophenylated thrombin by antithrombin iii in the presence of heparin.
17:383-391.
1980
-
Simplification of the sequential impedance plethysmograph technique without loss of accuracy.
17:561-565.
1980
-
The effect of aspirin inhibition of PGI2 production on platelet adherence to normal and damaged rabbit aortae.
17:453-464.
1980
-
Comparison of the haemorrhagic effects of porcine and bovine heparin in rabbits.
15:581-586.
1979
-
Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and thigh vein thrombosis in patienis undergoing elective knee surgery.
16:37-45.
1979
-
Increased dipyridamole plasma concentrations associated with salicylate administration. Relationship to effects on platelet aggregation in vivo.
15:813-820.
1979
-
Prevention of venous thrombosis by intermittent sequential calf compression in patients with intracranial disease.
15:611-616.
1979
-
Prostaglandins I2 and E1 reduce rabbit and human platelet adherence without inhibiting serotonin release from adherent platelets.
15:273-279.
1979
-
The influence of heparin, NaCl and CaCl2 on the rate of the thrombin-antithrombin III reaction.
15:821-834.
1979
-
The value of adding impedance plethysmography to 125I-fibrinogen leg scanning for the detection of deep vein thrombosis in high risk surgical patients: A comparative study between patients undergoing general surgery and hip surgery.
15:227-234.
1979
-
Uncontrolled PGI2 production by whole vessel wall segments due to thrombin generation and its prevention by heparin.
16:551-555.
1979
-
The effect of acetylsalicylic acid and indomethacin on rabbit platelet adherence to collagen and the subendothelium in the presence of a low or high hematocrit.
13:971-981.
1978
-
The prolonged effect of sulfinpyrazone on collagen-induced platelet aggregation in vivo.
13:883-892.
1978
-
Inhibition of thrombin by antithrombin III in the presence of certain glycosaminoglycans found in the mammalian aorta.
13:655-670.
1978
-
A comparison of the effects of aspirin and dipyridamole on platelet aggregation in vivo and ex vivo.
13:517-529.
1978
-
Determination of sulphinpyrazone in patient plasma by gas chromatography.
12:247-255.
1978
-
Synergism between platelet aggregating agents: The role of the arachidonate pathway.
11:567-580.
1977
-
The inactivation of thrombin and plasmin by antithrombin III in the presence of Sepharose-heparin.
10:645-660.
1977
-
Adsorption on glass and polyethylene from solutions of fibrinogen and albumin.
9:249-259.
1976
-
Flow patterns in a platelet adhesion test cell - Implications for adhesion measurement.
9:133-142.
1976
-
Responses to Aggregating Agents after Cleavage of GPIb of Human Platelets by the O-Sialoglycoprotein Endoprotease from Pasteurella haemolytica— Potential Surrogates for Bernard-Soulier Platelets? \textbar Request PDF
2000
-
Effects of ethanol on rabbit platelet responses to collagen in vitro and ex vivo and on platelet adhesion to de-endothelialzed aortae in vivo \textbar Request PDF
1987
-
Comparison of methods of measuring loss of cytoplasmic constituents from platelets
1976
-
Effect of diet-induced hyperlipidemia on in vitro-function of rabbit platelets
1976
-
Effect of ionophore A23, 187 on thrombin-degranulated washed rabbit platelets
1975
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)